染色体不稳定性与EGFR-TKI耐火性非小细胞肺癌中的cGAS-STING激活有关
Kimio Yonesaka1, Takashi Kurosaki1, Junko Tanizaki1,2
1Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
Cells
|March 26, 2025
概括
染色体不稳定性 (CIN) 激活了cGAS-STING通路,导致一些非小细胞肺癌 (NSCLC) 患者对表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 的耐药性. 通过逆转促进瘤的变化,阻止这种途径恢复了EGFR-TKI的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 对EGFR突变的非小细胞肺癌 (NSCLC) 至关重要.
- 然而,不一致的疗效和获得的耐药性限制了它们的长期益处.
- 除了二次突变之外,抗性的机制仍然不完全理解.
研究的目的:
- 研究染色体不稳定性 (CIN) 在介导NSCLC中对EGFR-TKI的耐药性的作用.
- 阐明将CIN与EGFR-TKI折射性联系起来的分子途径.
- 探索针对CIN诱导的耐药性的治疗策略.
主要方法:
- 转录组分析以确定由CIN.激活的途径.
- 细胞模型的CIN (H1975dnMCAK细胞) 来评估EGFR-TKI反应.
- 对cGAS-STING信号激活和下游效应 (例如IL-6) 的评估.
- 在染色体不稳定的NSCLC中评估上皮层-介质细胞过渡 (EMT).
- 在体外和体外实验中测试cGAS-STING-TBK1信号的阻断.
主要成果:
- 发现CIN可以激活EGFR突变NSCLC的一个子集中的cGAS-STING信号通路.
- 具有CIN的H1975dnMCAK细胞显示对奥西默提尼布的折射性,与激活的cGAS-STING和IL-6信号相关.
- 染色体不稳定的NSCLC表现出增强的EMT.
- 抑制cGAS-STING-TBK1信号反转了EMT,并恢复了对EGFR-TKI的敏感性.
结论:
- 染色体不稳定可能通过cGAS-STING通路激活在一些NSCLC患者中驱动EGFR-TKI耐药性.
- 这种途径的激活促进EMT,有助于治疗的折射性.
- 针对cGAS-STING-TBK1轴提供了一种潜在的策略,以克服CIN阳性NSCLC中EGFR-TKI耐药性.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.1K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
992
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer-Critical Genes I: Proto-oncogenes
8.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
